Table 3.

Crude and adjusted odds ratios for factors associated with trial reporting

Variables	Crude odds ratio (95% CI)	P value	Adjusted odds ratio (95% CI)	P value
Completion year:
Increase of one year	0.98 (0.96 to 0.99)	0.005	1.05 (1.03 to 1.07)	<0.001
Phase:
Discordant	1.69 (1.03 to 2.74)	0.04	1.48 (0.75 to 2.89)	0.26
I	4.31 (1.28 to 14.53)	0.02	2.26 (0.50 to 10.28)	0.29
II	0.63 (0.56 to 0.70)	<0.001	1.09 (0.93 to 1.26)	0.29
III	Reference
IV	0.30 (0.26 to 0.34)	<0.001	1.13 (0.92 to 1.38)	0.26
Sponsor class:
Non-commercial	Reference
Commercial	17.17 (14.89 to 19.80)	<0.001	23.25 (19.15 to 28.24)	<0.001
Mixed	30.19 (15.76 to 57.81)	<0.001	15.52 (7.29 to 33.01)	<0.001
Blank	1.40 (0.48 to 4.08)	0.54	2.27 (0.70 to 7.36)	0.17
Part of paediatric investigation plan	3.23 (2.07 to 5.03)	<0.001	1.09 (0.59 to 2.01)	0.79
Condition being studied is rare disease:
No	Reference
Yes	0.88 (0.75 to 1.05)	0.15	0.96 (0.76 to 1.22)	0.74
Discordant	2.77 (1.43 to 5.37)	0.003	0.78 (0.34 to 1.77)	0.55
Data not available	0.33 (0.18 to 0.59)	<0.001	0.62 (0.26 to 1.45)	0.27
Bioequivalence study	2.04 (0.51 to 8.17)	0.31	5.16 (0.89 to 29.82)	0.07
Participants are healthy volunteers	1.09 (0.93 to 1.28)	0.27	1.29 (1.03 to 1.62)	0.02
Total No of trials registered for trial’s sponsor:
First quarter (1-10)	Reference
Second quarter (11-53)	2.84 (2.44 to 3.31)	<0.001	5.99 (4.98 to 7.20)	<0.001
Third quarter (54-244)	6.57 (5.63 to 7.67)	<0.001	19.17 (15.54 to 23.64)	<0.001
Fourth quarter (274-1260)	15.67 (13.43 to 18.29)	<0.001	18.38 (15.31 to 22.06)	<0.001
All sites terminated	0.40 (0.35 to 0.46)	<0.001	0.55 (0.45 to 0.66)	<0.001
Unclear sponsor name given	0.03 (0.01 to 0.13)	<0.001	1.65 (0.36 to 7.47)	0.52
No of countries:
1	Reference
2	3.63 (3.13 to 4.21)	<0.001	1.31 (1.08 to 1.60)	0.01
≥3	7.34 (6.45 to 8.36)	<0.001	1.89 (1.58 to 2.26)	<0.001
Trial has multiple sponsors	1.13 (0.81 to 1.56)	0.48	1.63 (1.03 to 2.58)	0.04